127P Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer (NSCLC)?

L Hendriks,J Praag,A-M.C Dingemans,Marcel Westenend ,Cordula Pitz ,Dirk De Ruysscher ,Janna Schoenmaekers ,Harry J.m Groen ,A Chatterjee,Henry C Woodruff ,J Stigt,Ben Van Den Borne ,Gerbern P Bootsma ,Haiyan Zeng ,Hester A Gietema ,Simon Keek ,G Herder,J Belderbos,Hans Smit ,Philippe Lambin

doi:10.1016/j.annonc.2022.02.156

127P Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer (NSCLC)?

L Hendriks, J Praag + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.02.156

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Apr 1, 2022
Citations: 1	License type: publisher-specific-oa

Affiliation: Maastricht University, Erasmus University Rotterdam, Erasmus MC, VieCuri Medisch Centrum, Laurentius Ziekenhuis, Maastro Clinic, University Medical Center Groningen, Isala, Catharina Ziekenhuis, Radboud University Nijmegen, Zuyderland Medisch Centrum, Meander Medisch Centrum, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Rijnstate Hospital

#Cumulative Incidence Of Brain Metastasis #Brain Metastases In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Despite radical intent therapy for patients (pts) with stage III NSCLC, cumulative incidence of brain metastasis (BM) reaches 30%. Current risk stratification fails to identify these pts. Radiomics features (fts) from chest CTs have shown to have predictive value. We aimed to develop a model combining existing clinical risk factors with radiomics fts for BM development in stage III NSCLC.

Full Text